NSCLC metastatic/molecular target

Ongoing protocols: click on the protocol for the inclusion and exclusion criteria (update 10/01/2022)

EGFR common mutations
MARIPOSA-1 (Janssen Research & Development) (1st line) - exon 19 or exon 21
A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer.

MARIPOSA-2 (Janssen) (2nd line) - exon 19 or exon 21
A Phase 3, Open-Label, Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Osimertinib Failure
 
INSIGHT-2 (Merck) (2nd line) - EGFR + cMET amplification
A Study of Tepotinib Plus Osimertinib in Epidermal Growth Factor Receptor (EGFR ) Tyrosine Kinase Inhibitor (TKI) Relapsed Mesenchymal-epithelial Transition Factor (MET) Amplified Non-small Cell Lung Cancer (NSCLC).

FLOSI (Academic) (1st line) 
Local AblativeTherapy for Oligoprogressive Non-Small-Cell Lung Cancer Treated With First-line OSImertinib. 

EGFR uncommon mutations
ZENITH20 (Spectrum) (1st and 2nd line) - all
A Phase 2 Study of Poziotinib in Patients with Non-small cell Lung Cancer (NSCLC), Locally Advanced or Metastatic, with EGFR or HER2 Exon 20 Insertion Mutation.
(cohort 1-2-3-4 closed, cohort 5-6-7 open)

Papillon (Janssen) (1st line) - exon20 insertion
A Randomized, Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Patients With EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer.

ALK fusion
Currently no open trials

AKTmut
TAPISTRY (Roche) (1st and 2nd line)
Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study with Ipatasertib

KRAS G12C
CODEBREAK100 (Amgen) (2nd and further line)
A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of AMG 510 in Subjects With Solid Tumors With a Specific KRAS Mutation.

CJDQ443A12101 (Novartis) (2nd and 3rd line)
Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation.
(contact the study team to check whether one of the cohorts is open)

BI1823911 (Boehringer) (end-line)
A Study to Test Different Doses of BI 1823911 Alone and Combined With Other Medicines in People With Different Types of Advanced Cancer With KRAS Mutation. 
(contact the study team to check whether one of the cohorts is open)

RET
LIBRETTO-431 (Eli Lilly) (1st line) - RET fusion
A Multicenter, Randomized, Open-Label, Phase 3 Trial Comparing LOXO-292 to Platinum-Based and Pemetrexed Therapy With or Without Pembrolizumab as Initial Treatment of Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer.

BRAF
LXH254, LTT462 (Novartis) (end-line) - BRAF non-V600
A Phase Ib, open-label, multicenter study of oral LXH254 in combination with oral LTT462 in adult patients with advanced or metastatic KRAS or BRAF mutant Non-Small Cell Lung Cancer.
(only cohort for BRAF open)

C-MET
Currently no open trials

ROS1
TRIDENT-1 (TurningPoint) (1st, 2nd and 3rd line)
A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ROS1 or NTRK1-3 Rearrangements.

HER2 exon 20
ZENITH20 (Spectrum) (1st and 2nd line) 
A Phase 2 Study of Poziotinib in Patients with Non-small cell Lung Cancer (NSCLC), Locally Advanced or Metastatic, with EGFR or HER2 Exon 20 Insertion Mutation.
(cohort 1-2-3-4 closed, cohort 5-6-7 open)

TAPISTRY (Roche) (1st and 2nd line)
Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study with Trastuzumab-emtansine.
(currently on hold)

PYRAMID-1 (Jiangsu) (2nd line)
A Phase 3, Randomized, Open-label, Multicenter Study of the Efficacy and Safety of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC) Harboring a HER2 Exon 20 Mutation Who Progressed on or After Treatment With Platinum Based Chemotherapy.

NTRK
TRIDENT-1 (TurningPoint)  (1st, 2nd and 3rd line)
A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ROS1 or NTRK1-3 Rearrangements.

PIK3CA
TAPISTRY (Roche) (1st and 2nd line)
Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study

NRG1 fusion
MCLA-128-CL01 (Merus) (any line)
A Phase I/II Study of MCLA-128 (zenocutuzumab), a full length IgG1 Bispecific Antibody Targeting HER2 and HER3, in Patients with Solid Tumors

3th line (all mutations)
ImmunoSABR (Academic)
Combination of SABR and L19-IL2 in Patients With Stage IV Lung Cancer.